Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.55 |
| ▸ | WIZ | O95785 | 5/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24079567 | 0.92 | CRBN (0.54) | CRBNWIZIKZF2CSNK1A1GSPT1 | |
| SCHEMBL25996845 | 0.89 | CRBN (0.56) | CRBNWIZIKZF2CSNK1A1GSPT1 | |
| SCHEMBL25087685 | 0.86 | CRBN (0.60) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25087686 | 0.86 | IKZF2 (0.56) | CRBNWIZIKZF2CSNK1A1GSPT1 | |
| SCHEMBL25087603 | 0.86 | CRBN (0.53) | CRBNWIZIKZF2CSNK1A1GSPT1 | |
| SCHEMBL25087699 | 0.85 | CRBN (0.61) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25087680 | 0.85 | IKZF2 (0.60) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL27115056 | 0.83 | IKZF2 (0.59) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25087626 | 0.83 | CRBN (0.61) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL24760675 | 0.83 | WIZ (0.55) | CRBNWIZIKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | CRBN 3703/4885WIZ 1518/4885IKZF2 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.